PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
复制标题
DOI：
10.1002/ijc.25634
复制
发表时间：
2011-02-15
影响因子：
6.4
通讯作者：
Pollack, Alan
中科院分区：
文献类型：
--
作者：
Hensley, Harvey H.;Hannoun-Levi, Jean-Michel;Hachem, Paul;Mu, Zhaomei;Stoyanova, Radka;Khor, Li-Yan;Agrawal, Sudhir;Pollack, Alan
The therapeutic efficacy of Gem®231, a second generation antisense molecule targeted to the RIα subunit of PKARIα (AS-PKA), administered in combination with androgen deprivation (AD) and radiation therapy (RT), was examined in androgen sensitive (LNCaP) and insensitive (PC3) cell lines. Apoptosis was assayed by Caspase 3+7 activity and AnnexinV binding. AS-PKA significantly increased apoptosis in vitro from RT (both lines), with further increases in LNCaP cells grown in AD medium. In LNCaP cells, AD increased phosphorylated map-kinase (pMAPK), which was reduced by AS-PKA relative to the MM controls. AS-PKA also reduced pMAPK levels in PC3 cells. Cell death was measured by clonogenic survival assays. In vivo, LNCaP cells were grown orthotopically in nude mice. Tumor kinetics were measured by magnetic resonance imaging and serum prostate-specific antigen. PC3 cells were grown subcutaneously and tumor volume assessed by caliper measurements. In PC3 xenografts, AS-PKA caused a significant increase in tumor doubling time relative to MM controls as a monotherapy or in combination with RT. In orthotopic LNCaP tumors, AS-PKA was ineffective as a monotherapy; however it caused a statistically significant increase in tumor doubling time relative to MM controls when used in combination with AD, with or without RT. PKARIα levels in tumors were quantified via immunohistochemical (IHC) staining and image analysis. IHC measurements in LNCaP cells showed that AS-PKA reduced PKARIα levels in vivo. We demonstrate for the first time that AS-PKA enhances cell killing androgen sensitive prostate cancer cells to AD±RT and androgen insensitive cells to RT.
登录
查看更多内容
DOI：
10.1196/annals.1281.028
发表时间：
2003-01-01
期刊：
THERAPEUTIC OLIGONUCLEOTIDES
影响因子：
--
作者：
Mani, S;Goel, S;Cho-Chung, YS
通讯作者：
Cho-Chung, YS
DOI：
10.1073/pnas.86.13.4887
发表时间：
1989-07-01
影响因子：
11.1
作者：
MELLON, PL;CLEGG, CH;MCKNIGHT, GS
通讯作者：
MCKNIGHT, GS
DOI：
10.1016/s0360-3016(02)02707-4
发表时间：
2002-06-01
影响因子：
7
作者：
Kestin, LL;Vicini, FA;Martinez, AA
通讯作者：
Martinez, AA
影响因子：
12.8
作者：
Chin, C;Bae, JH;Kim, SH
通讯作者：
Kim, SH
DOI：
10.1089/oli.1.2000.10.423
发表时间：
2000-12-01
期刊：
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT
影响因子：
--
作者：
Nesterova, M;Cho-Chung, YS
通讯作者：
Cho-Chung, YS